Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access.

BACKGROUND Care of patients with end-stage renal disease (ESRD) is important and resource intense. To enable ESRD programs to develop strategies for more cost-efficient care, an accurate estimate of the cost of caring for patients with ESRD is needed. METHODS The objective of our study is to develop an updated and accurate itemized description of costs and resources required to treat patients with ESRD on dialysis therapy and contrast differences in resources required for various dialysis modalities. One hundred sixty-six patients who had been on dialysis therapy for longer than 6 months and agreed to enrollment were followed up prospectively for 1 year. Detailed information on baseline patient characteristics, including comorbidity, was collected. Costs considered included those related to outpatient dialysis care, inpatient care, outpatient nondialysis care, and physician claims. We also estimated separately the cost of maintaining the dialysis access. RESULTS Overall annual cost of care for in-center, satellite, and home/self-care hemodialysis and peritoneal dialysis were US $51,252 (95% confidence interval [CI], 47,680 to 54,824), $42,057 (95% CI, 39,523 to 44,592), $29,961 (95% CI, 21,252 to 38,670), and $26,959 (95% CI, 23,500 to 30,416), respectively (P < 0.001). After adjustment for the effect of other important predictors of cost, such as comorbidity, these differences persisted. Among patients treated with hemodialysis, the cost of vascular access-related care was lower by more than fivefold for patients who began the study period with a functioning native arteriovenous fistula compared with those treated with a permanent catheter or synthetic graft (P < 0.001). CONCLUSION To maximize the efficiency with which care is provided to patients with ESRD, dialysis programs should encourage the use of home/self-care hemodialysis and peritoneal dialysis.

[1]  R. Feachem,et al.  Getting more for their dollar: a comparison of the NHS with California's Kaiser Permanente. , 2002, BMJ.

[2]  B. Manns,et al.  The Southern Alberta Renal Program database: a prototype for patient management and research initiatives. , 2001, Clinical and investigative medicine. Medecine clinique et experimentale.

[3]  G. Nassar,et al.  Infectious complications of the hemodialysis access. , 2001, Kidney international.

[4]  Third Nkf-K Doqi III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  M. Oliver,et al.  Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. , 2001, Kidney international.

[6]  M. Saul,et al.  A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. , 2000, The American journal of medicine.

[7]  C. Tomson,et al.  Recent advances: nephrology. , 2000, BMJ.

[8]  R. Wolfe,et al.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. , 1999, The New England journal of medicine.

[9]  A. Collins,et al.  Mortality risks of peritoneal dialysis and hemodialysis. , 1999, American Journal of Kidney Diseases.

[10]  A. Levin,et al.  Clinical practice guidelines for the delivery of hemodialysis. Canadian Society of Nephrology. , 1999, Journal of the American Society of Nephrology.

[11]  R. Hirth,et al.  Practice patterns, case mix, Medicare payment policy, and dialysis facility costs. , 1999, Health services research.

[12]  B. Allard,et al.  A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis vs. self-care in-center hemodialysis in france , 1999 .

[13]  A. Levin,et al.  Clinical practice guidelines for the delivery of hemodialysis , 1999 .

[14]  G A de Wit,et al.  Economic evaluation of end stage renal disease treatment. , 1998, Health policy.

[15]  R. Foley,et al.  Mode of dialysis therapy and mortality in end-stage renal disease. , 1998, Journal of the American Society of Nephrology : JASN.

[16]  A. Culyer,et al.  Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. , 1998, Health technology assessment.

[17]  H. Morrison,et al.  Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  F. Dekker,et al.  Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. The Necosad Study Group. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  P Menè,et al.  Calcium channel blockers: what they can and what they can't do. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  J. Yudkin,et al.  Proteinuria and progressive renal disease: birth weight and microalbuminuria. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  A. Laupacis,et al.  A study of the quality of life and cost-utility of renal transplantation. , 1996, Kidney international.

[22]  S. Prichard Treatment Modality Selection in 150 Consecutive Patients Starting Esrd Therapy , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[23]  R. Goeree,et al.  Cost analysis of dialysis treatments for end-stage renal disease (ESRD). , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[24]  R. Wolfe,et al.  A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[25]  B. Croxson,et al.  A cost effectiveness analysis of the treatment of end stage renal failure. , 1990, The New Zealand medical journal.

[26]  T. Garner,et al.  Cost-effectiveness Analysis of End-stage Renal Disease Treatments , 1987, Medical care.

[27]  G. Torrance,et al.  Measurement of quality of life in end-stage renal disease: the time trade-off approach. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.

[28]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[29]  R. Guttmann,et al.  Transplantation and home hemodialysis: their cost-effectiveness. , 1985, Journal of Chronic Diseases.

[30]  G. Torrance,et al.  A Cost-Effectiveness Analysis of Continuous Ambulatory Peritoneal Dialysis and Hospital Hemodialysis , 1984 .

[31]  L. Guernsey Self-care for the ESRD patient. , 1982, Nephrology nurse.

[32]  Anne Ludbrook,et al.  A cost-effectiveness analysis of the treatment of chronic renal failure , 1981 .

[33]  K. Thompson Cost comparison of in-center dialysis, home dialysis, and transplantation in the Nashville area. , 1980, Nephrology nurse.

[34]  M. Bryant Arrhythmias and the dialysis nurse. Some to be aware of--some to beware of. , 1980, Nephrology nurse.